Patient-specific neoepitope-Major Histocompatibility Complex class I complex (Neoepitope-MHC-I)

Patient-specific neoepitope-Major Histocompatibility Complex (MHC) class I complexes are molecular assemblies consisting of a mutated peptide (neoepitope) derived from tumor-specific somatic mutations and an MHC class I molecule. These complexes are presented on the surface of malignant cells, serving as highly specific markers that distinguish cancer cells from healthy tissue (Nature Reviews Cancer, 2020). Because neoepitopes arise from non-synonymous mutations unique to the patient's tumor, they are not subject to central thymic tolerance, making them potent targets for immunotherapy (Science, 2017). Therapeutic strategies targeting these complexes include personalized cancer vaccines, which prime the immune system to recognize these specific markers, and adoptive cell therapies using T-cell receptors (TCRs) engineered to bind the neoepitope-MHC complex (Journal of Hematology & Oncology, 2021). The interaction between the T-cell receptor and the neoepitope-MHC complex triggers a cytotoxic immune response, leading to the selective destruction of tumor cells. However, challenges such as HLA down-regulation and the high degree of heterogeneity in neoantigen expression remain significant hurdles in clinical application (Nature, 2019).

Other names

Tumor-specific neoantigen-MHC complexNeoantigen-HLA class I complexMutant peptide-MHC complexTSA-MHC complexPersonalized neoantigen-MHC complex

Recognition of the neoepitope-MHC complex by specific T-cell receptors (TCRs) on CD8+ T cells, which triggers the release of perforins and granzymes, leading to targeted tumor cell lysis (Nature Reviews Cancer, 2020; Journal of Hematology & Oncology, 2021).